# A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

Study · id `cardio:ct-nct04825743` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04825743](<https://clinicaltrials.gov/study/NCT04825743>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04825743

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2463 participants.

## Technical summary

Registry record NCT04825743. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-24 (actual); primary completion 2026-05-13 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2463 participants (enrolled count; ClinicalTrials.gov record NCT04825743, source copy `cardio:ctgov-nct04825743-2025-10-23`, retrieved 2026-10-26)
- Started: 2021-04-24 (actual) (ClinicalTrials.gov record NCT04825743, source copy `cardio:ctgov-nct04825743-2025-10-23`, retrieved 2026-10-26)
- Primary completion: 2026-05-13 (anticipated) (ClinicalTrials.gov record NCT04825743, source copy `cardio:ctgov-nct04825743-2025-10-23`, retrieved 2026-10-26)
- Completion: 2026-05-13 (anticipated) (ClinicalTrials.gov record NCT04825743, source copy `cardio:ctgov-nct04825743-2025-10-23`, retrieved 2026-10-26)
- Countries: United States; Canada; Czechia; France; Hungary; Mexico; Netherlands; Romania (ClinicalTrials.gov record NCT04825743, source copy `cardio:ctgov-nct04825743-2025-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04825743-2025-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
- Acronym: CELEBRATE
- Condition: ST-elevation Myocardial Infarction (STEMI)
- Intervention (Drug): zalunfiban
- Intervention (Drug): Placebo
- Lead sponsor: CeleCor Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI (`cardio:pubmed-42303064`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c1b40e46d60959f3bf775273197e83e8aaed198eb7c73d36e428e4f087b7c2af
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
